Juvenile Idiopathic Arthritis (JIA): KOL Insights on Treatment Practices and Unmet Needs

  • ID: 1939916
  • Drug Pipelines
  • 116 Pages
  • Sociable Pharma
1 of 5


  • Abbott
  • Bristol-Myers Squibb
  • Janssen Biotech
  • Novartis
  • Roche
  • Sanofi
  • MORE
In-depth primary research was conducted in the US and across Europe with seven key opinion leaders in juvenile idiopathic arthritis (JIA) to understand how therapy use will change in the future. A key theme in this research is the management and implementation of ‘step-up’ treatment strategies to optimize the timing of effective forms of therapy. The view is that this is the major macro-trend that will alter treatment strategy, generating new treatment challenges and presenting opportunities for current and future market players.

Understand key treatment trends including:
- Aggressive versus conservative approaches
- Strategies for treating oligoarthritis, polyarthritis and systemic arthritis
- Long-term patient management on biologic therapies

Identify unmet needs including:

- Managing corticosteroid therapy
- Initiating methotrexate
- Initiating biologic therapy
- Treating sacroiliac juvenile arthritis
- Discontinuing methotrexate and biologics: managing patients with inactive disease
- Treating patients with systemic JIA

Key features:

- 4 treatment maps & 18 treatment settings: A visual guide to the treatment of juvenile idiopathic arthritis, based on extensive primary and secondary research

- Analysis of current US/EU treatment practices involving 7 drug classes: Corticosteroids, synthetic disease-modifying antirheumatic drugs, anti-TNF therapies, anti-interleukins, anti-CD20 antibodies, other biologics and non-steroidal anti-inflammatory drugs

- 9 unmet needs identified: Based on KOL interviews and literature research
Note: Product cover images may vary from those shown
2 of 5


  • Abbott
  • Bristol-Myers Squibb
  • Janssen Biotech
  • Novartis
  • Roche
  • Sanofi
  • MORE
Executive Summary

Juvenile arthritis therapy: not much is for certain
- Traditional step-up treatment strategies still dominate
- Conservative vs. early aggressive approach
- The glucocorticosteroid controversy
- Managing patients with no disease activity
- The future role of juvenile idiopathic arthritis therapies

Scope of Analysis
Research methodology
- Extensive secondary research
- In-depth primary research
Analysis synthesis
Products analyzed
Disease description
- Key points
- Symptom presentation
- Diagnosis
Disease classification
- Behavior of disease
- Extent of disease
Definitions for this analysis
Treatment Map summary

Current Treatment Practice
Key findings & trends
- Synthetic DMARDs: gold standard for all non-systemic forms of JIA
- Anti-TNF therapies: increasing drive to use biologics early
- Anti-interleukins: therapy access is key issue in systemic JIA
- T-cell inhibitors: third-line treatment for systemic JIA
- Anti-CD20 antibodies: option of =last resort‘
- Glucocorticoids: significant differences in current practice between doctors
- NSAIDs: now used far more sparingly in JIA
- Other therapy options
Synthetic disease-modifying antirheumatic drugs
Anti-TNF therapies
Anti-CD antibodies
Other biologics
Non-steroidal anti-inflammatory drugs
Other therapies

Treatment Challenges
Key findings & trends
- Early switch to anti-TNF therapy: benefits vs. potential threats
- Early initiation of methotrexate: how early is early enough?
- Managing patients with inactive disease and patients who flare-up while on medication after years of inactive disease
- Choice of biologic and switching within class: lack of data to make an evidence-based decision
- Treatment personalization: using genetics and autoantibody profiles to tailor pharmacotherapy
- Access to specialist healthcare and parent/patient education
Challenge matrix
Large impact, smaller patient groups
- Non-response to biologics and loss of response over time
- Managing systemic arthritis
- Discontinuing methotrexate and biologics – managing patients with inactive disease
Small impact, smaller patient groups
- Treating sacroiliac juvenile arthritis
Large impact, sizable patient groups
- Managing glucocorticosteroid therapy
- Initiating methotrexate
- Initiating biologic therapy
- Access to specialist healthcare
Small impact, sizable patient groups
- Patient and parental attitudes, education and transition to adult care

List of figures

Figure 1: Factors influencing the earlier use of biologics in juvenile idiopathic arthritis
Figure 2: Aggressive vs. conservative treatment strategies in juvenile idiopathic arthritis
Figure 3: Summary of juvenile idiopathic arthritis Treatment Map
Figure 4: Key treatment challenges in juvenile idiopathic arthritis

List of tables

Table 1: Key current brands and pipeline products for the treatment of juvenile idiopathic arthritis, by drug class
Table 2: Juvenile idiopathic arthritis subtypes, characteristics and prevalence
Note: Product cover images may vary from those shown
3 of 5


4 of 5
- Sanofi
- Pfizer
- Barr
- Sellec Chemicals
- Janssen Biotech
- Abbott
- UCB Pharma
- Swedish Orphan
- Roche
- Novartis
- Roche
- Genentech
- Bristol-Myers Squibb
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown